Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

  • 0 views
  • 24 Nov, 2021
  • 1 location
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.

  • 0 views
  • 19 Jun, 2021
  • 20 locations
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies

serum pregnancy test
lymphoma
renal function
solid tumour
antibiotics
  • 18 views
  • 18 Dec, 2021
  • 11 locations
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21

renal function tests
carcinoma
malignant peripheral nerve sheath tumor
nitrosoureas
monoclonal antibodies
  • 2 views
  • 16 Dec, 2021
  • 24 locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy

  • 2 views
  • 29 Jan, 2021
  • 54 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination

  • 0 views
  • 19 Jul, 2021
  • 2 locations
Testing the Addition of Tazemetostat to the Immunotherapy Drug Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma

This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has

  • 41 views
  • 10 Dec, 2021
  • 27 locations
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to

ejection fraction
lymphoma
gilbert's syndrome
renal function
measurable disease
  • 10 views
  • 07 Aug, 2021
  • 31 locations
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat

This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.

renal function tests
serum pregnancy test
lymphoma
copper
renal function
  • 0 views
  • 12 Jan, 2022
  • 7 locations
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

The primary aim of the phase 1 portion of the trial is to establish the recommended phase 2 dose (RP2D) of tazemetostat in combination with a fixed dose of pembrolizumab in patients with

  • 0 views
  • 01 May, 2021
  • 1 location